Skip to main content

Table 9 Studies reporting measures of fatal and non-fatal overdose

From: The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review

Study

Measure

Control Group

Intervention Group

Statistical Test or Model

p-value

Estimate of Effect

Direction of Effect

Overall Effect Direction

(S2) Aldabergenov et al., 2022 [70]

Methadone-related deaths among people prescribed methadone

44 (95% CI: 37–50)a

55b

NR

 ≥ 0.05*

NR

Favours control

Mixed

Buprenorphine-related deaths among people prescribed buprenorphine

2016: 1

2017: 1

2018: 1

2019: 1c

2020: 1d

NR

NR

NR

None

(S3) Amram et al., 2021 [71]

Emergency department visits related to overdose

16e

15f

Chi-square, McNemar’s chi-square or Fisher’s exact test

1

NR

Favours intervention

Positive

Odds of emergency department visit per one-dose difference in total take-home doses after regulatory changes

NR

NR

Generalized linear model with binary logistic function

1.73

Adjusted OR: 0.94 (0.86–1.03)

Favours intervention

(S6) Corace et al., 2022 [74]

Self-reported opioid overdose(s) with or without emergency department visit

13%g

16%h

Chi square test

0.54

χ2: 0.37

Favours control

Negative

(S8) Ezie et al., 2022 [76]

“Overdose”, details not specified

2%e

0.7%f

Chi square test

 > 0.05

NR

Favours intervention

Positive

(S13) Gomes et al., 2022 [81]

Non-fatal opioid overdosesi among clients receiving daily methadone at baseline

9.5% per person-yeark

6.9%/person-yearl

Cox proportional-hazards model

 < 0.05*

Weighted HR: 0.73 (95% CI: 0.56–0.96)

Favours intervention

Mixed

Non-fatal opioid overdosesi among clients receiving 5–6 take-home doses of methadone at baseline

1.8%/person-yeark

1.4%/person-yearm

Cox proportional-hazards model

 ≥ 0.05*

Weighted HR: 0.80 (95% CI: 0.50–1.28)

Favours intervention

Fatal opioid overdosesj among clients receiving daily methadone at baseline

0.5% per person-yeark

0.6%/person-yearl

Cox proportional-hazards model

 ≥ 0.05*

Weighted HR: 1.26 (95% CI: 0.48–3.33)

Favours control

Fatal opioid overdosesj among clients receiving 5–6 take-home doses of methadone at baseline

0.3%/person-yeark

NRm,n

Cox proportional-hazards model

 ≥ 0.05*

Weighted HR: 0.48 (95% CI: 0.16–1.45)

Favours intervention

Non-fatal opioid overdosesi among clients receiving daily buprenorphine/ naloxone at baseline

3.5%/person-yeark

6.5%/person-yearm

Cox proportional-hazards model

 ≥ 0.05*

Weighted HR: 1.86 (95% CI: 0.70–4.92)

Favours control

Non-fatal opioid overdosesi among clients receiving 5–6 take-home doses of buprenorphine /naloxone at baseline

1.4%/person-yeark

1.7%/person-yearm

Cox proportional-hazards model

 ≥ 0.05*

Weighted HR: 1.23 (95% CI: 0.58–2.63)

Favours control

(S17) Joseph et al., 2021 [85]

Non-fatal overdoseso

2e

6f

NR

NR

NR

Favours control

Mixed

Fatal overdoseso

1e

0f

NR

NR

NR

Favours intervention

(S26) Nguyen et al., 2021 [94]

Fatal overdosest among clients “established” in care without take-home doses at baseline

0.5%q

0.6%r

NR

 ≥ 0.05*

NR

Favours control

Mixed

Fatal overdosesp among clients “established” in care with take-home doses at baseline

4.1%s

0.8%t

NR

 ≥ 0.05*

NR

Favours intervention

  1. Where adjusted and unadjusted effect estimates were reported, we present adjusted estimates. Where weighted and unweighted effect estimates were reported, we present weighted estimates. In no case did this change the overall estimated direction of effectAcronyms: HR hazard ratio, NR not reported, OR odds ratio, RR relative risk
  2. *Not reported in the original study; inferred or calculated by authors
  3. aControl group: Projected deaths of methadone clients, Mar.-Jun. 2020
  4. bIntervention group: Actual deaths of methadone clients, Mar.–Jun. 2020
  5. cControl group: Buprenorphine clients, 2016–2019
  6. dIntervention group: Buprenorphine clients, 2020
  7. eControl group: OAT clients pre-pandemic
  8. fIntervention group: OAT clients post-pandemic
  9. gControl group: OAT clients without additional take-home doses during pandemic
  10. hIntervention group: OAT clients with additional take-home doses during pandemic
  11. i ≥ 1 emergency department visit or inpatient hospitalization for opioid toxicity
  12. jCoroner-confirmed fatal opioid overdoses
  13. kControl group: OAT clients without additional take-home doses during pandemic
  14. lIntervention group: OAT clients with additional take-home doses (any number) during pandemic
  15. mIntervention group: Clients with additional take-home doses (at least a two-week supply) during pandemic
  16. nCould not be modelled because of small numbers
  17. oOverdoses reported to clinical personnel or documented in medical records
  18. pFatal overdoses ascertained from electronic health records; defined as death [over 10-month follow-up period] with any or multiple illicit substances (including opioids) listed as any of the potential causes of death
  19. qControl group: Clients who never had take-home doses (neither before nor during pandemic)
  20. rIntervention group: Clients newly started on take-home doses during pandemic
  21. sControl group: Clients with no change or a decrease in take-home doses during pandemic
  22. tIntervention group: Clients with additional take-home doses during pandemic